Please listen to the article
This audio is automatically generated. Please let us know if you have feedback.
Diving brief:
Health supply chain costs and pharmaceutical costs are expected to rise modestly between July 2025 and June 2026. New study From the healthcare service company VIZIENT.
Pharmacy expenditure rises by 3.8 %, and some are driven by increased demand for special drugs. ABBVIE's autoimmune disease drug Fumira continues to be the most popular drug for total expenditures, but popular GLP-1, such as Ozempic, WEGOVY, and Mounjaro, is in the top 10 pharmaceuticals in total expenditures. It is predicted.
According to the report, the cost of the supply chain will increase by about 2 % during the period, following the price of raw materials, the increase in cargo and shipping, cargo costs, tariffs, and tariffs.
Dive insight:
Providers are increasingly concerned Increase of drugs and supply chains 2025Expert told Healthcare Dive last month. Vizient Report adds fuel to these fears and shows a slight increase in spending to come this summer.
According to reports, the increase in demand for private drugs and individualized drugs will promote some of the increase in pharmaceutical spending. High -cost drugs already account for 54 % of the total drug spending nationwide, and it is expected that more drugs will be brought to the market or marked up for inflation.
It is expected that the number of special and complex medicines on the market will increase by 4.4 % during the period.
According to the report, the acquisition of Gurkagon-like peptide-1 or GLP-1 drugs and the increase in prescriptions (GLP-1) also contribute to the rise in pharmaceutical costs.
Currently, one in eight adults in the United States has said that GLP-1 is using GLP-1, and in the first three quarters of 2024, the total expenditure of drugs has risen to $ 57.5 billion. vizient。
However, the main propulsion of specialized pharmaceutical costs is Steven Lucio, a classic specialized medicine that treats oncology and autoimmune disorders due to rising prices. Vizient's insight and intellectual principal told Healthcare Dive in January.
During the survey period, Fumira, Stellala, and Scariidi (all can treat Crohn's disease) are expected to have the largest price increase.
According to Vizient, the healthcare industry also increases costs related to supply chain pressure.
According to the report, the Biden administration approved the increase in tariffs of $ 18 billion in May in May. A syringe is used to supply liquid to the body and is important for a wide range of healthcare services.
Medical providers performed lobby activities behind the scenes to postpone tariffs until 2026, but providers need to diversify the supply chain from Chinese suppliers to limit the impact of tariffs. Was described.
According to the report, the customs duties for specific face masks and medical and surgical gloves have increased earlier this year.
Additional tariffs from the Trump administration can cause a higher rate of supply chain costs. On Saturday, Trump stated that it would increase tariffs on imports. Moves that may increase the price of medical devices such as Canada, China, Mexico -X -ray devices.
Providers are starting to deal with market concerns on rising supply chain costs.
HCA Healthcare's recent calls on investors have discussed the procedures that HCA has taken to strengthen supply chain resilience by discussing the fourth quarter revenue.
CFO Mike Marks stated that the company had diversified supply chains for many years than customs duties to alleviate its impact, concluding a fixed -price contract in 2025.
